nancy snyderman - May 14, 2025 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Director
Signature
/s/ Jason Cavalier, Attorney-in-Fact for Nancy Lynn Snyderman, M.D.
Stock symbol
LYRA
Transactions as of
May 14, 2025
Transactions value $
$0
Form type
4
Date filed
5/16/2025, 04:30 PM
Previous filing
Nov 15, 2024
Next filing
May 23, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
snyderman nancy lynn MD Director C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN /s/ Jason Cavalier, Attorney-in-Fact for Nancy Lynn Snyderman, M.D. 2025-05-16 0001675198

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Restricted Stock Units Award $0 +32K $0.00 32K May 14, 2025 Common Stock 32K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.